"Arthritis"

Golimumab biosimilar for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis

Etanercept (Rymti) - rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis Skip to main contentSkip to "About this site"Basic HTML versionGovernment of CanadaSearch and menusSearch and menusYou are here:HomeAll ServicesHealthDrugs, health & consumer productsReview DecisionsSummary Basis of Decision - Rymti - Health CanadaDrugsNatural for the following indications:Treatment of moderately to severely active rheumatoid arthritis (RA) in adults. Treatment is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function. Rymti can be initiated in combination with methotrexate (MTX) in adult patients or used alone.Reducing signs and symptoms

Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT) Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT) | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Journals Journals * About journals * Efficacy and Mechanism Evaluation * Global Health * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Efficacy and Mechanism Evaluation Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT) 1. Journals Library 2. Efficacy and Mechanism Evaluation 3. Rheumatoid Arthritis Prevention: catalysing

Gait Rehabilitation for Early Rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial 1. Journals Library 2. Health Technology Assessment 3. Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial * Type: Research Article Our publication formats * Authors: Gordon J Hendry, Lindsay Bearne, Linda

Tocilizumab (Tyenne) - rheumatoid arthritis, juvenile idiopathic arthritis or juvenile idiopathic polyarthritis Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. EMA/358138/2023 EMEA/H/C/005781 Tyenne (tocilizumab) An overview of Tyenne and why it is authorised in the EU What is Tyenne and what is it used for? Tyenne is a medicine used to treat: • adults with severe rheumatoid arthritis that is getting worse, who have not been previously treated with a medicine

Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) Technology appraisal guidance Published: 13 June 2024 www.nice.org.uk/guidance/ta982 © NICE 2024. All rights reserved. Subject to Notice of rights ( Advice ................................................................................................................................3 Information ..................................................................................................................................3 Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminatedappraisal) (TA982)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2of 3 Advice NICE is unable to make a recommendation about the use in the NHS

Yoga as an adjunctive therapy for rheumatoid arthritis. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effect and safety of yoga as an adjunctive therapy for rheumatoid arthritis.

Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline * Per Olav Vandvik ## Abstract **Clinical question** In adult patients with inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis), or psoriasis taking biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care? **Context and current practice** Standard care for immune mediated inflammatory

Rheumatoid arthritis - Scenario: Confirmed Rheumatoid arthritis Cookies on the NICE website and servicesCookies are files saved on your phone, tablet or computer when you visit a website.We use cookies to store information about how you use the NICE website and services, such as the pages you visit.For more information, view our cookie statement.(Opens in a new window)Accept all cookiesReject : Confirmed rheumatoid arthritisFrom age 16 years onwards.What drug treatments may be offered in secondary care for rheumatoid arthritis?A treat-to-target strategy is used — the aim is to achieve a target of remission or low disease activity if remission cannot be achieved. Specialists will usually offer a conventional disease-modifying anti-rheumatic drug (cDMARD) as monotherapy, ideally within 3 months

Rheumatoid arthritis - When to suspect Rheumatoid arthritis Cookies on the NICE website and servicesCookies are files saved on your phone, tablet or computer when you visit a website.We use cookies to store information about how you use the NICE website and services, such as the pages you visit.For more information, view our cookie statement.(Opens in a new window)Accept all cookiesReject people click on these adverts.Show vendors within this categoryMarketing and advertising cookiesOnOffSkip to contentAccessibility helpSearch CKS…Search CKS…Skip to contentMenuNICECKSHealth topics A to ZRheumatoid arthritisDiagnosisWhen to suspect RARheumatoid arthritis:When should I suspect rheumatoid arthritis?Last revised in January 2024SummaryHave I got the right topic?How up-to-date is this topic

Rheumatoid arthritis - Investigations for suspected Rheumatoid arthritis Cookies on the NICE website and servicesCookies are files saved on your phone, tablet or computer when you visit a website.We use cookies to store information about how you use the NICE website and services, such as the pages you visit.For more information, view our cookie statement.(Opens in a new window)Accept all , or by measuring how many times people click on these adverts.Show vendors within this categoryMarketing and advertising cookiesOnOffSkip to contentAccessibility helpSearch CKS…Search CKS…Skip to contentMenuNICECKSHealth topics A to ZRheumatoid arthritisDiagnosisInvestigations for suspected RARheumatoid arthritis:What investigations are necessary for suspected rheumatoid arthritis?Last revised in January

Rheumatoid arthritis - Scenario: Suspected Rheumatoid arthritis Cookies on the NICE website and servicesCookies are files saved on your phone, tablet or computer when you visit a website.We use cookies to store information about how you use the NICE website and services, such as the pages you visit.For more information, view our cookie statement.(Opens in a new window)Accept all cookiesReject care.SummaryHave I got the right topic?How up-to-date is this topic?Goals and outcome measuresBackground informationDiagnosisManagementScenario: Suspected RAScenario: Confirmed RASupporting evidenceHow this topic was developedReferencesOn this pageManagement of suspected RAScenario: Suspected rheumatoid arthritisFrom age 16 years onwards.How should I manage suspected rheumatoid arthritis?Refer people

Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthriti Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis ========================================================================================================================================================================================================== * Andreas Kerschbaumer * Josef S Smolen * Ricardo J O Ferreira * Heidi Bertheussen * Xenofon Baraliakos * Daniel Aletaha * Dennis G McGonagle * Désirée van der Heijde * Iain B McInnes * Bente

Joint Care? Report on the care received by children & young people diagnosed with juvenile idiopathic arthritis (JIA) 2025/PROF/507 © The Royal College of Ophthalmologists 2025 All rights reserved. For permission to reproduce any of the content contained herein please contact contact@rcophth.ac.uk Joint Care? A report on the care received by children and young people who are diagnosed with juvenile idiopathic arthritis (JIA) NCEPOD Report Summary for UK ophthalmologists (and eye health and care professionals). The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) has recently published findings from a national enquiry into JIA care. The report confirmed that timely diagnosis, prompt referral, and early access to medication can transform the outcomes and experience

Adalimumab (Hulio) - rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uv Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment

Adalimumab (Abrilada) - rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment

Infliximab (Ixifi) - Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis or plaque psoriasis Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel

Assessment of seronegative arthritis Skip to main contentSkip to searchLog inEnglish#{autosuggest.search}#{autosuggest.search}Assessment of seronegative arthritis MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:31 Dec 2023Last updated:25 Jan 2024SummarySeronegative arthritis describes a group of conditions that present with inflammatory arthritis but without a positive rheumatoid factor, hence seronegative.A detailed history and a thorough physical examination should enable the diagnosis to be elucidated in most patients. Supporting or confirmatory data are obtained from laboratory and imaging studies.Spondyloarthropathies, crystalline and viral arthropathies, and rheumatoid arthritis are the most common diagnoses in these patients.[1][2]DifferentialsCommonAnkylosing

Bimekizumab for treating active psoriatic arthritis Bimekizumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 October 2023 www.nice.org.uk/guidance/ta916 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility The recommendations in this guidance represent the view health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bimekizumab for treating active psoriatic arthritis (TA916)© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

Methotrexate for juvenile idiopathic arthritis. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. Methotrexate has broad immunomodulatory properties and is the most commonly used disease-modifying antirheumatic drug (DMARD). This is an update of a 2001 Cochrane review. It supports a living guideline for children and young people with JIA. To assess the benefits and harms of methotrexate for children and young people with juvenile idiopathic arthritis. The Australian JIA Living Guideline Working Group created a registry of all randomised controlled trials (RCTs) of JIA by searching CENTRAL, MEDLINE, Embase, and trials registries. The date of the most recent search of online databases was 1 February 2023. We searched for RCTs that compared methotrexate